Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Public ClinicalTrials.gov record NCT02587650. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Study identification
- NCT ID
- NCT02587650
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- University of California, San Francisco
- Other
- Enrollment
- 1 participant
Conditions and interventions
Conditions
- ALK Fusion Protein Expression
- BRAF wt Allele
- Invasive Skin Melanoma
- MET Fusion Gene Positive
- NRAS wt Allele
- NTRK1 Fusion Positive
- NTRK2 Fusion Positive
- NTRK3 Fusion Positive
- RET Fusion Positive
- ROS1 Fusion Positive
- Stage III Cutaneous Melanoma
- Stage IIIA Cutaneous Melanoma
- Stage IIIB Cutaneous Melanoma
- Stage IIIC Cutaneous Melanoma
- Stage IV Cutaneous Melanoma
Interventions
- Capmatinib Drug
- Ceritinib Drug
- Entrectinib Drug
- Laboratory Biomarker Analysis Other
- Regorafenib Drug
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2015
- Primary completion
- Jul 11, 2018
- Completion
- Jul 11, 2018
- Last update posted
- Jan 26, 2020
2015 – 2018
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, San Francisco | San Francisco | California | 94115 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02587650, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2020 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02587650 live on ClinicalTrials.gov.